Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 1,000 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $2.02 during mid-day trading on Tuesday, reaching $111.43. 621,570 shares of the company’s stock were exchanged, compared to its average volume of 668,162. The business’s fifty day simple moving average is $110.58 and its 200 day simple moving average is $109.59. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.48. The firm has a market capitalization of $6.88 billion, a PE ratio of 18.80, a P/E/G ratio of 1.38 and a beta of 0.57.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. LSV Asset Management increased its holdings in Jazz Pharmaceuticals by 4.2% in the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after acquiring an additional 99,705 shares during the last quarter. Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after acquiring an additional 527,187 shares during the period. Capital World Investors purchased a new stake in Jazz Pharmaceuticals during the first quarter valued at about $171,943,000. Finally, Baupost Group LLC MA boosted its position in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada raised their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Piper Sandler lowered their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Robert W. Baird reduced their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.43.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.